ATLANTA (Reuters Health) Mar 18 – Statin therapy at the time patients undergo percutaneous coronary intervention (PCI) appears to lower mortality significantly, according to an analysis of outcomes 6 months after the procedure.
Dr. Albert W. Chan, of the Cleveland Clinic, presented the findings here Sunday on opening day of the 51st Annual Scientific Session of the American College of Cardiology.
In a prospective study of a total of 6647 patients who underwent PCI between 1993 and 1999, 23.5% were treated with statins at the time of the intervention.
Statin therapy was associated with a 60% lower mortality at 30 days and a 37% reduction at 6 months. The 6-month mortality rates in the two groups were 3.1% in the statin group versus 4.9% in the non-statin group (p = 0.003).
According to the researchers, the mortality benefit was independent of myocardial infarction at the time of procedure, recurrent MI, and target vessel revascularization. The findings also held true regardless of the patients' gender or whether they had diabetes or unstable angina, they report.
"This study, which supports previous research showing the early benefits of statin therapy for heart attack patients, shows that statin therapy is also associated with a mortality benefit early after coronary angioplasty and stenting," Dr. Chan asserted in a written release.